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Indirect anticoagulants such as warfarin are the ‘gold standard’ for prevention and treatment of thromboembolic
complications in patients at risk (in atrial fibrillation of valvular and nonvalvular etiology, the presence of artificial
heart valves, orthopedic and trauma interventions, and other pathological conditions). A wide range of doses
required to achieve a therapeutic effect indicates the need for a personalized approach to the appointment of
warfarin. In addition to the dependence on the patient's clinical characteristics (sex, age, smoking status, diagnosis),
there is a clear association between the warfarin dose and the carriage of certain allelic variants of key genes that
makes it possible to apply molecular genetic testing for individual dose adjustment. This provides a more rapid
target anticoagulant effect and also reduces the risk of bleeding associated with a possible overdose of warfarin.
Implementation of this approach will allow more wide and safe application of indirect anticoagulants in Russia for
needy patients.Review
Introduction
Pharmacogenomics is an important part of personalized
medicine which implies that a physician chooses drugs
and their doses taking into account individual genetic
characteristics of a patient (Figure 1). The danger of re-
ceiving indirect anticoagulants is associated with an
overdose of the drug that leads to bleeding of varying se-
verity. Moreover, sometimes there is no effect of the
treatment in spite of the increase in the dose. Existing
methods of the choice of warfarin doses should be
improved including molecular genetic analysis of key
drug metabolism genes in the diagnostic algorithm.
Warfarin is an oral anticoagulant widely used around
the world. For the first time, this drug was synthesized in
the laboratory of Karl Link in Wisconsin in 1948, and
since the 1950s, it was introduced into clinical practice.* Correspondence: gl62@mail.ru
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distribution, and reproduction in any mediumWarfarin is commonly used for prevention of thrombo-
embolism in patients with chronic thrombus (blood clot)
formed, for example, in atrial fibrillation, prosthetic heart
valves and deep venous thrombosis, and for stroke preven-
tion in patients with atrial fibrillation [2,3]. Anticoagulants
play a special role in the prevention of thromboembolic
complications of cardiovascular diseases. CVD is one of
the major targets for predictive, preventive and persona-
lized medicine. A lot of investigations are aimed at identi-
fying risk factors for cardiovascular diseases and
prevention strategies [4-7]. For example, in Japan, the
combination of public health and personalized treatment
activities had contributed to substantial decline in mortal-
ity from stroke and ischemic heart disease between the
1960s and 2000s [7].
Thrombosis is a life-threatening condition and one of
the main causes of mortality and disability, bringing
huge economic loss in Russia. Major complications of
anticoagulant therapy are bleeding, which are observed
in about 8% of patients receiving warfarin for a year.
One percent of them are classified as severe cases (intra-
cranial, retroperitoneal) resulting in hospitalization orntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 Clinical potential of pharmacogenomics. Patients with the same diagnosis are usually treated in the same way, although their
responses to drug therapy will not be the same. Pharmacogenetics has the possibility to predict those patients who are likely to have the desired
response to the drug, those who are likely to have little or no benefit and those at risk for toxicity (adapted from [1]).
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in the patient's death.
The molecular target of warfarin is the enzyme vita-
min K-epoxide reductase (VKOR), which reduces the
oxidized form (epoxide) of vitamin K to hydroquinone
(Figure 2). The reduced vitamin K (hydroquinone) is a
cofactor of gamma-glutamyl carboxylase (GGCX),
which, in turn, provides the carboxylation and, thereby,
activates coagulation factors II, VII, IX, and X and pro-
teins C, S, and Z. Warfarin inhibits VKOR that leads to
a less reduced form of vitamin K needed for carboxyl-
ation of clotting factors [2,8].
Warfarin is a racemic molecule due to the asymmetry
of the first aliphatic carbon atom. Clinically available
warfarin is a mixture of 50% R- and 50% S-warfarin.
Cytochrome P450 2C9 catalyzes the conversion of S-
warfarin to an inactive metabolite, 6-hydroxy-S-warfarin,
and 7-hydroxy-S-warfarin. CYP 1A1, 2C19, and 3A4 are
responsible for metabolism of R-warfarin, which is five
times less potent as an inhibitor of VKOR, so its meta-
bolic outcome is much less important in the general
scheme of the action of warfarin (Figure 3) [2].
Patients show a wide range of interindividual differ-
ences in drug doses of warfarin needed to achieve the
desired therapeutic effect measured by the international
normalized ratio (INR) (Figure 4). This parameter char-
acterizes the patient's plasma clotting time when added
to plasma thromboplastin, an activator of blood coagula-
tion. Usually at the beginning of the treatment, a dose of
5 mg/day is assigned; however, the requirement for a
dose to achieve the desired INR value may vary from 1 to
20 mg/day. This variation is caused by different factors.
The external factors include nutrition, smoking, and con-
comitant drugs, and the internal ones are genetic factors,
age, gender, and body mass index. Environmental andgenetic factors cause about 17% and 50% of the variabil-
ity in warfarin dose, respectively; unknown factors con-
tribute 33% in the variability [2,8].
Effect of nongenetic parameters
Easily accessible patient characteristics such as gender,
age, body mass index, the interaction with concomitant
drugs, smoking, ethnicity, etc., according to some data,
provide 20–40% of the variability in warfarin dose
(Figure 5). This information is often used for dose selec-
tion for patients [11]. It is known that for every 10-kg in-
crease in the patient weight suggests an increase in the
daily dose by about 1 mg. According to different studies,
the body mass index may explain the warfarin dose vari-
ability from 1% (patient group from Sudan, p= 0.04) to
2.3% (patient group from China, p= 0.026) and 5.7%
(European patients) [12-14]. A tendency to reduce the
need for warfarin doses is observed with increasing age;
this figure may contribute from 2% to 9% in the dose
variability [13-15]. Smoking and pulmonary embolism
can lead to the increase in the dose of warfarin (p= 0.025
and 0.0059, respectively) [15]. The interaction of co-
medication is also an important factor affecting the dose
that makes 3–4% of interindividual variability [12,14].
According to some studies, amiodarone, which increases
the anticoagulant effect of warfarin, may contribute up to
20% in the dose variability (p < 0.001) [13].
Role of polymorphic variants of the VKORC1 gene
According to literature data, polymorphic variants of the
vitamin K-epoxide reductase complex subunit 1 gene
(VKORC1), which is a target of warfarin, make a max-
imal contribution to the dose variability of this drug.
VKOR is a small (18 kDa, 163 amino acid residues)
transmembrane protein of the endoplasmic reticulum; it
Figure 2 Warfarin pathway, pharmacodynamics. The coagulation cascade requires vitamin K in the reduced form as a cofactor for gamma-
glutamyl carboxylase to convert inactive factors II, VII, IX, and X to the active forms. Vitamin K is oxidized during this process to vitamin K epoxide.
The enzyme VKOR converts vitamin K epoxide back into reduced vitamin K. Warfarin inhibits VKOR, decreasing vitamin K availability, diminishing
activatable factors II, VII, IX, and X, and thus inhibiting coagulation (adapted from [2] and [9]).
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and pancreas. The VKORC1 gene encoding vitamin K-
epoxide reductase is located at chromosome 16p11.2
and has three exons. Since its opening in 2004, many
studies have been performed concerning the influence of
VKORC1 polymorphisms on the need of doses of oral
anticoagulants [17,18].
Clinically important polymorphic variants of the
VKORC1 gene are -1639G>A (rs9923231) in the promoter
region, 1173C>T (rs9934438), 1542G>C (rs8050894),
2255T>C (rs2359612), 3730G>A (rs7294) in introns, and
30-untranslated regions of the gene. These polymorphic
loci are in linkage disequilibrium and lead to a change in
the amount of produced mRNA [2,14]. Rieder et al. sug-
gest a designation of the -1639A, 1173T, 1542C, 2255C,
and 3730A allele combination as haplotype A and the
-1639G, 1173C, 1542G, 2255T, and 3730G allele combin-
ation as haplotype B [19]. Haplotype A contains allelicvariants of the VKORC1 gene associated with a low ex-
pression of the protein that, consequently, requires a smal-
ler concentration of warfarin to achieve a pharmacological
effect (Figure 6). The average values of warfarin doses in
patients carrying these haplotypes in different races are
presented in Table 1.
The data show that patients carrying at least one copy
of haplotype B receive a higher warfarin dose than
homozygous carriers of haplotype A. The dose for the
BB genotype is higher by 30% and 80% than that for the
AB and AA genotypes, respectively. It is believed that
carriers of haplotype B produce two times more mRNA
than carriers of haplotype A [2]. D’Andrea et al. studying
the influence of polymorphic substitutions in VKORC1
on the activity of the VKOR protein, did not reveal any
alternative mRNA splicing caused by one nucleotide
substitution at position 1173 in the VKORC1 gene. The
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Figure 3 Metabolism of warfarin. Warfarin, an enantiomeric mixture of equal concentrations of R- and S-forms, is 93 ± 8% absorbed from the
gastrointestinal tract. The rate of metabolism for S-warfarin is approximately three times (3×) faster than that for R-warfarin [2].
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alter the activity of VKOR [20]. Yuan et al. showed that
-1639G>A can be that variant [21]. The substitution at
position −1639 in the promoter is located in the E-box
(CA/GNNTG); another three E-boxes were found a short
distance from this place (200 np). The consensus sequence
of the E-box is CANNTG. It was shown that E-boxes are
important elements for mediating the cell/tissue type-
specific transcription, e.g. in the muscles, neurons, liver,
and pancreas [22,23]. The replacement of the second base
A by G, as it is observed in locus −1639, disturbs the con-
sensus of the E-box and changes the promoter activity.Figure 4 Variability in warfarin dosing at steady state. In any given pa
than an order of magnitude (adapted from [10]).It has been clearly demonstrated that in the HepG2
cell line (human hepatoma cells), the promoter activ-
ity was increased by 44% when changing the consen-
sus sequence (A>G). This suggests that the E-box in
HepG2 could function as a repressor binding site,
and since the line was derived from HepG2 hepatoma,
it is likely that the −1639 E-box could also inhibit tran-
scription in the liver [21].
Bodin et al. suggested that the substitution at pos-
ition −1639 is located in the binding site of transcription
factor NF1 (TTGGCCA) [24]. However, the full consensus
sequence for NF1 TTGG (A/C) N5GCCAA is not observedtient population, the daily therapeutic warfarin dose will vary by more
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Figure 5 Factors that correlate with warfarin dose. A number of factors affect warfarin dosing, including nongenetic factors (drug-drug
interactions, environmental factors, diet, alcohol consumption, and smoking) and genetic factors. Genetic factors explain about 40% of warfarin
dosing variability (adapted from [16]).
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located at the place of the second «N», where any nucleo-
tide is suitable for the binding of the transcription factors.
The authors also found no difference in the promoter activ-
ity between alleles −1639 A and G [24,25]. However, a
number of factors may explain the discrepancy between the
results of Bodin et al. and Yuan et al. Cloned promoter
regions differ by several base pairs (from −35 to −1798 in
the study of Yuan et al. and from −12 to −1756 in the study
of Bodin et al.). It should be noted that these authors used
different transfection methods: Bodin et al. used calcium
phosphate, whereas Yuan et al. used lipofectamine
since the calcium phosphate method was less efficient
in their study [21,24].Figure 6 Effect of VKORC1 haplotype A or B on warfarin dosage. The
the daggers denote p< 0.05 for the comparison with haplotype A/B. The TThe fact that individuals with the GG genotype of
polymorphic locus -1639G>A require a higher dose of
warfarin can be explained by the following: the increase
in the VKORC1 promoter activity leads to the enhance-
ment of the mRNA expression from the VKORC1 gene
and, thereby, to increased translation of the VKORC1
protein. The elevated level of mRNA of VKORC1 can re-
sult in the higher VKOR activity and, consequently, en-
hance the efficiency of the regeneration of reduced
vitamin K, which ultimately can provide the higher level
of gamma-carboxylation of vitamin K-dependent coagu-
lation factors. The increased number of active clotting
factors leads to an increase in the warfarin dose to
achieve the anticoagulation effect [17,21].asterisks denote p< 0.05 for the comparison with haplotype A/A, and
bars represent standard errors (adapted from [15]).
Table 1 Average dose of warfarin for patients carrying
different haplotypes of VKORC1
Number of patients Average dose (mg/day)
VKORC1AA VKORC1AB VKORC1BB
603 (White race) 3.1 4.4 5.7
408 (Asian origin) 3.1 3.8 5.6
96 (African origin) 3.7 4.9 6.0
Group A is associated with a low warfarin dose, and group B, with a high
warfarin dose [2].
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iants (−1639G>A (rs9923231), 1173C>T (rs9934438),
and 2255T>C (rs2359612)) appeared to be the most im-
portant for predicting the variability in warfarin dose.
The greatest frequency of occurrence of the minor allele
in the Caucasoid population is shown to be 0.391 for
polymorphic variant -1639G>A. The coefficient of deter-
mination (R2) calculated for a given allele was 0.317, the
highest among all other R2 values calculated for single-
nucleotide substitutions in both the VKORC1 gene and
other genes. None of the other ten flanking single-
nucleotide substitutions predict an additional variability
in dose [14].
The study of patients living in the West Siberian region
of Russia showed significant differences in average daily
doses of warfarin depending on the VKORC genotype [26].
Among molecular genetic markers, the VKORC genotype
makes a maximal contribution in the choice of the thera-
peutic warfarin dose in the West Siberian population.
Role of polymorphic variants of the CYP2C9 gene
Metabolism of warfarin with the CYP2C9 enzyme
encoded by the CYP2C9 gene also influences the warfarin
dose. Aithal et al. in 1999, for the first time, reported an
association between the CYP2C9 genotype and the war-
farin dose: patients with a low need for warfarin dose
(N=36) had one or more allelic variants of CYP2C9 (com-
pared with patients bearing normal alleles, odd ratio
(OR)= 6.2 (95% confidence interval (CI) 2.48–15.6)) [27].

























Figure 7 CYP2C9 polymorphisms and warfarin dose. Bar graph showin
dose. *1/*1 is homozygous wild type and other labels show variants (adapshowed more complications during the treatment with
warfarin (OR = 5.97, 95% CI 2.26–15.82), and these
patients had an increased risk of serious bleeding (rate
ratio 3.68, 95% CI 1.43–9.50) compared with a randomly
selected control group [27].
Several polymorphic variants of the CYP2C9 gene are
identified to reduce the enzyme activity, which leads to
an increase in the warfarin concentration in blood serum
and frequent bleeding. The CYP2C9*1 allele is consid-
ered as the norm [2]. The most common structural poly-
morphisms of the CYP2C9 gene are R144C (CYP2C9*2)
and I359L (CYP2C9*3). The frequency of the CYP2C9*2
allele is 11–15% in Caucasoid populations and 2–3% in
African and Asian populations; the frequency of the
CYP2C9*3 allele is 5–7% and 2–4%, respectively [3,28].
According to the majority of data in vitro, the presence
of allele *2 does not significantly disturb the affinity for
the substrate. However, the maximum rate of metabol-
ism (Vmax) reduces by about 50% compared to the level
of the CYP2C9*1 allele that leads to a lower rate of war-
farin clearance. Amino acid substitution Ile359Leu cor-
responding to allele *3 results in a significant decrease
in the enzyme activity (up to 80%). Carriage of the
CYP2C9*2 allele leads to a decrease in warfarin dose
by 40% and 68% in heterozygotes and homozygotes,
respectively, and carriage of the CYP2C9*3 allele, by
40% and 85%, respectively [2] (Figure 7).
In sum, the cluster of the CYP2C9 gene on chromosome
10 is the second of the most associated with warfarin dose
region after the VKORC1 gene. This region of loci with
high coefficients of linkage disequilibrium includes the
CYP2C9, CYP2C8, CYP2C18, and CYP2C19 genes. Several
polymorphic variants of this locus were associated with
warfarin dose even after correction for multiple test-
ing [14]. Functional polymorphic variant CYP2C9*3
(rs1057910, Ile359Leu), which greatly limits the hydroxyl-
ation of S-warfarin, was the most associated with warfarin
dose in this region (R2 = 0.141) according to Wadelius
et al. [14]. Functional polymorphic variant CYP2C9*2
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g the relationship of cytochrome P450 2C9 genotype and warfarin
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cant in univariate analysis. In this study, the additional
genotyping of 53 single-nucleotide substitutions was per-
formed: 17, 10, 14, and 12 in the regions of the CYP2C9,
CYP2C19, CYP2C18, and CYP2C8 genes, respectively. In
univariate analysis, a significant association was observed
apart from rs1057910 (*3) for nine single-nucleotide
polymorphisms (SNPs) including CYP2C19 50 up-
stream rs3814637 (R2 = 0.106, minor allele frequency
(MAF) = 0.059), the *15 allele and the intronic CYP2C18
rs7896133 (R2 = 0.074, MAF=0.056). The CYP2C19*2A
allele, which leads to the inactivation of the CYP2C19 en-
zyme, was not associated with the warfarin dose as in earl-
ier studies [14,30-33].
Alleles *2 and *3 of theCYP2C9 gene are less common
among the African population than among Europeans;
CYP2C9*2 is virtually absent in East Asian populations,
and *3 allele is also found with a small frequency. How-
ever, other polymorphic variants of the CYP2C9 gene
affecting the variability in warfarin dose are found in
these populations. In the study of 203 patients from
Sudan, the CYP2C9*3 (rs1057910) allele was not found
at all, and the CYP2C9*2 allele was revealed at a fre-
quency of approximately 5%. The minor alleles,
CYP2C9*5, *8, and *11 were detected at a frequency of
1% each, while CYP2C9*6 and *11, at a frequency of 2%
and 5%, respectively. The presence of *2, *5, *6, and *11
alleles decreased the warfarin dose by 16–33% as com-
pared to homozygotes *1/*1, and the dose was not
reduced in carriers of *8 and *9 alleles. In this study,
polymorphic variants*2, *5, *6, and *11 of the CYP2C9
gene have made 5% of the variability in warfarin dose in
patients (p < 0.0001) [12].
In the study of indigenous peoples in Indonesia
(N=122), the CYP2C9*2 allele was not identified, and
CYP2C9*3 was found with a frequency of 3.6% and had
no effect on the warfarin dose (N=85, p=0.9308). In this
study, the identified polymorphic variant G/A rs17847036
in the second exon of the CYP2C9 gene (MAF=1.8%)
contributed to the sensitivity to warfarin with p= 0.005.
This polymorphic variant along with nongenetic predic-
tors such as age, body mass, and growth of the patients
explained 14.5% of interindividual variability in warfarin
dose [34].
Contribution of polymorphic variants of the CYP4F2 gene
Another gene, CYP4F2, which may be considered as a pre-
dictor of warfarin dose, encodes cytochrome P450 mono-
oxygenase. Caldwell et al. showed that polymorphic
substitution C>T rs2108622 (Val433Met) in the CYP4F2
gene leads to an increase in the dose requirements of war-
farin in the European-American patients. Later, three
independent groups of patients showed that this poly-
morphic variant increases the dose by 1 mg/day incarriers of the T/T genotype compared with C/C (i.e. by
4–12% per C allele) [35].
McDonald et al. proposed a mechanism that explains
the effect of the rs2108622 allele on warfarin dose. They
showed that the CYP4F2 enzyme functions as vitamin
K1-monooxygenase, which generates, probably, omega-
hydroxy derivative of the substrate. CYP4F2 may be an
important complement to VKOR to limit the excessive
accumulation of vitamin K. Carriers of the Val433Met
allele of the CYP4F2 gene have reduced ability to
metabolize vitamin K1 due to the rs2108622-dependent
reduction of the constant concentration of the enzyme
in the liver. Thus, patients with polymorphic variant
rs2108622 are predisposed to an increased level of vita-
min K1 in the liver and have, therefore, a higher dose re-
quirement for warfarin to achieve therapeutic results. In
this study, polymorphic variant Val433Met was signifi-
cantly associated with the warfarin dose (p= 0.02) [36].
The contribution of the CYP4F2 gene in the variability
in warfarin dose was 1–5% according to various sources
[13,37]. Not in all cases, however, polymorphic variant
rs2108622 considerably influences the dose. In the study
of indigenous Indonesians, MAF of the Val433Met allele
was 18.85%; however, it was not significantly associated
with warfarin dose (p= 0.9394) [34].
Polymorphic variants of other genes
In addition to genes VKORC1 and CYP2C9, polymorphic
variants of other genes involved in the warfarin effect
may be important, for example, genes GGCX (encodes
gamma-glutamyl carboxylase), PROC (encodes C protein),
EPXH1 (encodes epoxide hydrolase), FVII (encodes clot-
ting factor VII), CALU (encodes calumenin), and APOE
(encodes apolipoprotein).
Contribution of polymorphic variants of the GGCX gene
Rieder et al. sequenced the GGCX gene in 23 Europeans
and found 37 single-nucleotide substitutions in this
gene, three of which were located at the 50-end of the
promoter; five, in the coding region of the gene (two
nonsynonymous (Gln325Arg and Leu634Pro) and three
synonymous (His194His, Arg406Arg, Thr414Thr)); two,
in the 30-nontranslated region; five, at the 30-end of the
flanking region; and 22, in introns. Among 21 poly-
morphic substitutions containing over 5% MAF, six in-
formative substitutions (at positions 4046, 10067, 12970,
13333, 14101, and 14599) were selected for genotyping a
sample of Europeans (186 people). The substitution in
position 12970 (rs11676382; C/G 11%/89%) in intron
14 of the gene significantly influenced the warfarin dose in
all studied models (p < 0.05). In this study, polymorphic
substitution 12970C>G explained 2% variability in war-
farin dose as compared to 21% and 8% for VKORC1 and
CYP2C9, respectively. This polymorphism had a small but
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2.6 mg/day (GG) vs. 4.6 ± 2.2 mg/day (CC+CG)), redu-
cing it by 17% [38].
In other studies, polymorphic variant rs12714145 (in
position 3261) was also appreciable: it caused 3.3% of
the dose variability. It was shown that the dose of
warfarin tends to increase with increasing the number of
microsatellite repeats in intron 6 GGCX [39-41]. According
to Chen et al., haplotype containing microsatellites was
more significant than rs12714145 in intron 2, but both of
them did not reach statistical significance [14,39-41].
A later study of King et al. in 2010 showed that
rs11676382 C>G significantly influenced warfarin dose,
while rs12714145 G>A did not. Among 985 White race
and African-American patients, 117 (12%) had one or two
copies of the G allele of rs11676382. The average values of
therapeutic doses of warfarin were 4.9, 4.1, and 3.8 mg/day
for C/C, C/G, and G/G, respectively. This single-nucleotide
substitution was a significant predictor of dose in this study
(p=0.03) and was associated with a decrease in dose by
6.1% per G allele (95% CI 0.6–11.4%). Half of the patients
(n=492) had one or two copies of rs12714145 of the A al-
lele. However, this polymorphic substitution was not a sig-
nificant predictor of dose (p=0.39). The average dose was
4.7 mg/day for A/A or A/G and 5.1 mg/day for G/G [42].Contribution of polymorphic variants of the PROC gene
Protein C (the product of the PROC gene) is a vitamin K-
dependent serine protease, which destroys factors Va and
VIIIa. Antagonists of vitamin K can decrease the activity
of protein C and, probably, cause its degradation [43].
Four out of 13 single-nucleotide substitutions in the
PROC gene analyzed in the study of Wadelius et al. were
significantly associated with warfarin dose: rs1799809
A>G (MAF= 0.433) and rs2069901 T>C (MAF= 0.441)
in the 50-regulatory region of PROC, rs2069910 C>T
(MAF= 0.387) in intron 2, and rs2069919 G>A in intron
3 (MAF= 0.372). Two polymorphic variants in the pro-
moter and one in the third intron achieved significant
association with the dose after applying the Bonferroni
correction for multiple comparisons within a single gene,
which explained 7–9% of differences in warfarin dose
(p=0.0002–0.0015). PROC haplotypes were also signifi-
cantly associated with the dose but did not increase statis-
tical significance because the lowest value of p was
0.00136 [14].
Carlquist et al. studied the effect of polymorphic variant
A/G rs2069919 of the PROC gene on warfarin dose in 170
patients and found no significant relationship. Average
doses of warfarin for genotypes GG, GA, and AA were
33± 16, 32± 13, and 29± 10 mg/week (medians 30, 28, 26
mg/week), respectively (p trend= 0.42; F= 0.33, p=0.72)
[43]. Polymorphic variants rs2069920, rs1799808, andrs1799809 of the PROC gene also showed no effect on
warfarin dose in Indonesian patients [34].
Contribution of polymorphic variants of the FVII, APOE, and
CALU genes
The single-nucleotide substitution in the FVII gene pro-
moter in the position of -402G>A (rs570317) leads to
the increase in the transcription rate and the enhanced
level of FVII in plasma. Substitution 13407G>A (R353Q,
rs6046) in the coding region of the gene leads to the de-
crease in the expression of the FVII gene [44-47]. How-
ever, other studies do not confirm the effect of these
polymorphic substitutions on warfarin dose [40,48,49].
The authors of works [50-52] describe repeats (four to
seven) of 37 np in length in intron 7 of the FVII gene. It
was shown that the number of these intron repeats dir-
ectly correlates with the relative expression level of
mRNA [50-52]. However, the significant contribution of
these repeats in the variability of warfarin dose also was
not revealed [48]. Variants of the FVII gene resulting in
the reduced level of factor FVII may cause the sensitivity
to warfarin. Aquilante et al. studied 350 patients of vari-
ous nationalities and described the influence of poly-
morphic variant FVII D/I (deletion/insertion of 10 bp in
the gene promoter in position −323). The average war-
farin dose in carriers of D/D was higher by 3.6 mg/week
than that in carriers of D/I or I/I; FVII D/I contributed
1.3% in the dose variability in this group (p= 0.04) [49].
In the study of Wadelius et al., two single-nucleotide
substitutions in the APOE gene were also analyzed, which
determined the commonly used *Е2, *Е, and *Е4 allele
systems. Patients who carried the common *E4 allele
along with the rarer *E2 allele required higher doses than
those who carried *E3 (p=0.0057). This result was signifi-
cant after the Bonferroni correction for multiple compari-
sons within the APOE gene [14]. It was previously
reported that CYP2C9 extensive metabolizers, which were
homozygotes APOE*E4, required a higher warfarin dose
than other extensive metabolizers (p=0.0008) [53]. In an-
other study, however, APOE*E4 carriers in a homozygous
state required a reduced dose of the anticoagulant aceno-
coumarol [54]. The dependence of warfarin dose on the
genotype of polymorphic loci in the APOE gene among
the Italian population was not also confirmed [55]. These
contradictory results show that the association between
anticoagulant dose and the APOE gene is weak, if any.
The allele variants of the genes GGCX, F7, PROZ, F9,
EPHX1, CALU, NR1I2 (encodes the pregnane receptor),
and ORM1 and ORM2 (encode orosomucoid 1 and 2)
had a significant effect on warfarin dose alone but did not
pass the correction for multiple testing [14].
The EPHX1 gene encodes microsomal epoxide hydro-
lase, the supposed subunit of vitamin K-epoxide reductase,
which covers the binding site on the epoxide of vitamin K.
Table 2 Multiple regression analysis
Predictor SNP One-dimensional R2 p





PROC rs2069919 0.09 0.0416
Body weight 0.057 0.0075
EPHX1 rs4653436 0.048 0.1016
Drug interactions 0.036 0.0878
GGCX rs12714145 0.034 0.026
ORM1 rs1687390 0.026 0.0571
The analysis explains the 73% variance in warfarin dose in the study of
Wadelius et al. [14].
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high doses of warfarin in CYP2C9-extensive metabolizers
carrying nonsynonymous single-nucleotide substitution
rs1051740 (Tyr113His) in the EPHX1 gene. This fact was
not, however, confirmed by Wadelius et al., although they
showed that the replacement of rs4653436 in EPHX1
located at the 50-end insignificantly influenced the dose
(p=0.00848, R2 = 0.048) [14,56].
The CALU gene encodes the protein calumenin, which
binds to vitamin K-epoxide reductase and, probably, inhi-
bits the effect of warfarin [57,58]. Coding single-
nucleotide substitution in the CALU gene (Arg4Gln),
which presumably provides an increase in dose in patients
carrying alleles *1/*1 of the CYP2C9 gene and haplotype
BB of the VKORC1 gene, was not significantly associated
with the warfarin dose in the study of Wadelius et al.
[14,59]. However, the substitution of rs11653 in the
30-nontranslating region in CALU, nonsynonymous
rs2307040, and two intron substitutions rs339054 and
rs1006023 led to borderline p values <0.05. It was
shown that there is association of the warfarin dose with
rs3762055 located between ORM1 and ORM2, and the
haplotype covered this region (p=4.93 × 10−2). Finally, a
polymorphic Leiden variant in the FV gene (rs6025) had
no effect on the dose of warfarin in the study of Wadelius
et al. (p=0.4925) [14].
Models of relationship between warfarin dose and
genetic and nongenetic parameters
Wadelius et al. conducted an extensive study of variabil-
ity in genes encoding proteins that are thought to be
involved in the action and biotransformation of warfarin.
The authors performed genotyping (N= 201, European
patients) of polymorphic variants in 29 genes whose pro-
ducts are involved in the metabolism of warfarin and
examine them for association with warfarin dose. The
results showed that polymorphic loci in the genes
VKORC1, CYP2C9, CYP2C18, CYP2C19, PROC, APOE,
EPHX1, CALU, F7, GGCX, PROZ (encodes a protein Z),
F9 (encodes coagulation clotting factor IX), NR1I2, and
ORM1-ORM2 were significantly related to the dose
(p < 0.05). Polymorphic variants of the VKORC1, CYP2C9,
CYP2C18, and CYP2C19 genes were significant after ap-
plying the Bonferroni correction for multiple testing for
all genes studied (p < 0.000175). However, association
of CYP2C18 and CYP2C19 was fully explained by
linkage disequilibrium with the loci of CYP2C9*2
and/or *3. PROC and APOE were both significantly asso-
ciated with the dose after correction for the number of the
studied polymorphic substitutions only within the APOE
and PROC genes, respectively [14].
To explore the possibility of the model of prediction
of the warfarin dose, Wadelius et al. combined genes
with the greatest influence on warfarin dose (VKORC1,CYP2C9, and PROC) and the characteristics of the
patients (age, body mass, interactions with other drugs,
and indications for treatment) in a multiple regression
model. This model explained 62% of the dose vari-
ability. The authors then considered all associated genes
VKORC1, CYP2C9, CYP2C19, CYP2C18, PROC, APOE,
EPHX1, CALU, GGCX, and ORM1-2 in the model, which
explained 76% of interindividual variability in warfarin
dose. Variables with individual p values above 0.2 and a
low coefficient of determination (R2) were subsequently
removed step-by-step from the model. The achieved
model containing VKORC1, CYP2C9*2 and *3, PROC,
EPHX1, GGCX, ORM1-2, age, body mass, and drug inter-
actions explained 73% of the variability in warfarin dose
(Table 2) [14].
The multiple regression model in experiments in China
showed that the VKORC1 -1639G>A, alleles CYP2C9
and EPHX1 691A>G, as well as age and body mass,
explained approximately 76.8% of variability in the dose
for Chinese patients having heart valve replacement [60].
On the whole, the combination of VKORC1 -1639G>A,
CYP2C9 (*2 and *3), and clinical factors (e.g. age, sex,
weight, and amiodarone use) explains approximately
55% of the total variance in warfarin maintenance dose
in Caucasians and only about 25% among African-
Americans [61-64].
The pharmacogenetic algorithm of Gage et al. is widely
applicable due to the presence of the online resource [65],
which suggests professionals a free use of the technique in
exchange for the information about the results (Figure 8)
[63]. The equation uses a simple linear relationship; a re-
finement of the formula is only due to changes in coeffi-
cients. However, linear models are rarely observed in
living systems. It is necessary to create a new mathemat-
ical model, which would completely neutralize the risk of
excessive anticoagulation and lead to a significant increase
in safety of warfarin therapy.
Figure 8 Online pharmacogenetic algorithm [65].
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It is shown that the therapeutic dose of warfarin is influ-
enced by many factors, of which genetic factors contrib-
ute more than 50%. Haplotypes A and B of the VKORC1
gene make the main contribution to the choice of war-
farin dose and should be used for the preliminary gen-
etic examination.
In our study, we have registered a significant difference
in the average daily dose of warfarin depending on geno-





filling the passport of a 
Figure 9 Algorithm to work with the challenging group of patients.7.1 ± 2.3, 4.8 ± 1.9, and 2.8 ± 0.6 mg for patients with the
CC (BB), CT (BA), and TT (AA) genotypes, respectively.
The presence of ‘slow’ alleles of the CYP2C9 gene
(CYP2C9*2, CYP2C9*3) in a heterozygous state had no
reliable effect on the warfarin dose. However, their iden-
tification is necessary to assess the risk of bleeding. The
influence on the dose is reliable, and the risk of compli-
cations significantly increases for carriers of the homozy-
gous ‘slow’ CYP2C9 alleles; however, the frequency of




retation of the data
lized medical treatment;
patient receiving warfarin
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http://www.epmajournal.com/content/3/1/10knowledge, is about 0.5%. If the CYP2C9*2 and CYP2C9*3
alleles are revealed in patients, then patients require more
frequent monitoring of INR throughout the warfarin ther-
apy, particularly in the case of the appointment of add-
itional drugs metabolized by cytochrome CYP2C9.
According to our observations, the therapeutic dose of
warfarin in carriers of alleles *2,*3 of CYP2C9 is more
variable than that in patients with genotype *1*1. The
contribution of other genetic markers did not have a sig-
nificant clinical value in our study. The initial dose of
warfarin can be calculated in accordance with the results
of pharmacogenetic testing using an online calculator or
the ‘Pharmacogenetics’ module of the Russian program
PharmSuite [65,66]. The individual initial dose of war-
farin is calculated on the basis of the molecular genetic
test followed by the adjustment of drug dosage guided
by INR and in accordance with the instruction for med-
ical use. The results of the pharmacogenetic testing for
CYP2C9 and VKORC1 can predict the fluctuation range
of the daily maintaining dose of warfarin and the risk
of complications.
According to our data, the pharmacogenetic testing
for personalized warfarin dosing can help reduce the
time of the dose adjustment, decrease the frequency
of episodes of excessive anticoagulation and bleeding by
factors of 3 and 4.5, respectively, and minimize the ne-
cessity of hospitalization of patients with bleeding and
thrombotic complications by 43% and, ultimately, can lower
treatment costs. The pharmacogenetic approach for the ad-
justment of warfarin doses results in the average economic
benefit of 1,739.49 rubles (50 €) per patient/year [67]. To
confirm the benefits of the pharmacogenetic approach to
the dosage of warfarin over the traditional treatment for
Russian patients, a large-scale multicenter prospective study
is currently being conducted in Russia under the National
Project VARFAGEN.
Practical recommendations
It is advisable to recommend the following algorithm for
patients, the inhabitants of Western Siberia, which are
planned to be treated with warfarin (Figure 9):
1. General clinical testing, evaluation of initial INR,
genetic testing of haplotypes A and B of the
VKORC1 gene, and identification of the ‘slow’ alleles
CYP2C9*2 and CYP2C9*3 (for 24 h).
2. Calculation of initial and maintenance dose by using
an online calculator based on environmental factors
(initial and target INR, age, body weight, smoking
status, concurrent amiodarone, and/or statins
treatment) and identified genetic variants of the
VKORC1 and CYP2C9 genes.
3. Issuing to the patient a written report containing the
calculated dose of warfarin, the frequency of INRmonitoring, and recommendations for lifestyle to
reduce the risk of side effects. The last section should
contain information about the diet features
(consumption of vitamin K-containing products and
alcohol), the list of drugs, the combination of which
could theoretically change the therapeutic dose of
warfarin, and recommendation for actions in case of
necessary surgical procedures (e.g. tooth extraction).
4. Direct dialling to ‘doctor-patient relationship’.
Coworkers of the Clinical Department in the Center
of New Medical Technologies along with the Group of
Pharmacogenomics in the Institute of Chemical Biology
and Fundamental Medicine of the Siberian Division of
RAS have a possibility to adhere to the proposed algo-
rithm that allows one to most efficiently use warfarin and
minimize the risk of side effects. To address these issues,
we have created the room for patients under warfarin
therapy where molecular-genetic and biochemical studies
are performed and patients are followed over time.
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